Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08
Jamie E. Flerlage(St. Jude Children's Research Hospital), M Link(Stanford Medicine), John T. Lucas(Wake Forest University), Torunn I. Yock(Massachusetts General Hospital), Eric Larsen(University of Massachusetts Chan Medical School), Yiwang Zhou(St. Jude Children's Research Hospital), Monika L. Metzger(St. Jude Children's Research Hospital), M. Krasin(St. Jude Children's Research Hospital), Amy L. Billett(Harvard University Press), Lianna J. Marks(Stanford Medicine), Barry L. Shulkin(St. Jude Children's Research Hospital), Pedro de Alarcón(Illinois College), Jia Liang(St. Jude Children's Research Hospital), Scott C. Howard(Hospital Sant Joan de Déu Barcelona), Alison M. Friedmann(Harvard University), Howard J. Weinstein(Harvard University Press), SC Kaste(St. Jude Children's Research Hospital), Karen Marcus(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Donaldson Ss(Stanford Medicine), M M Hudson(St. Jude Children's Research Hospital), S Dixon(St. Jude Children's Research Hospital), Sandra Luna-Fineman(Children's Hospital Colorado), Ying Zheng(St. Jude Children's Research Hospital), Amy E. Geddis(Seattle Children's Hospital), Matthew J Ehrhardt(St. Jude Children's Research Hospital), Angela M. Feraco(Dana-Farber Cancer Institute)
Cited by 2
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes
|Cell|1989|877
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
|Cancer Cell|2012|722